Adicet Bio, Inc

Adicet Bio, Inc. is a biotechnology company founded in 2015 focused on the development of novel off-the-shelf allogeneic gamma delta T cell immune cell therapies for oncology and other indications. resTORbio, Inc. is a public, clinical-stage biopharmaceutical company that has been focused on developing innovative medicines that target the biology of aging to treat aging-related diseases. On April 29, 2020, resTORbio and Adicet announced a reverse merger which is expected to close in the second half of 2020.